Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

Open access

Published version of a preprint

Abstract

Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signaling axis on the acquisition of resistance to cetuximab in patients and cellular models. Experimental Design: Tissue samples were obtained from 37 patients with colorectal cancer who became refractory to cetuximab. Colorectal cancer cells sensitive to cetuximab were treated until resistant derivatives emerged. Mutational profiling of biopsies and cell lines was performed. Structural modeling and functional analyses were performed to causally associate the alleles to resistance. Results: The genetic profile of tumor specimens obtained after cetuximab treatment revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF, and PIK3CA genes, including two novel EGFR ectodomain mutations (R451C and K467T). Mutational profiling of cetuximab-resistant cells recapitulated the molecular landscape observed in clinical samples and revealed three additional EGFR alleles: S464L, G465R, and I491M. Structurally, these mutations are located in the cetuximab-binding region, except for the R451C mutant. Functionally, EGFR ectodomain mutations prevent binding to cetuximab but a subset is permissive for interaction with panitumumab. Conclusions: Colorectal tumors evade EGFR blockade by constitutive activation of downstream signaling effectors and through mutations affecting receptor–antibody binding. Both mechanisms of resistance may occur concomitantly. Our data have implications for designing additional lines of therapy for patients with colorectal cancer who relapse upon treatment with anti-EGFR antibodies. Clin Cancer Res; 21(9); 2157–66. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2821

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 271

Metadata

Authors
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., Iglesias, M., Gavilan, E., Corti, G., Hobor, S., Crisafulli, G., Salido, M., Sánchez, J., Dalmases, A., Bellmunt, J., De Fabritiis, G., Rovira, A., Di Nicolantonio, F., Albanell, J., Bardelli, A., & Montagut, C.
Affiliations
  • IFOM (IT)
  • 4Cancer Research Program, IMIM (Institut Hospital del Mar Investigacions Mediques), Hospital del Mar, Barcelona, Spain.
  • Candiolo Cancer Institute (IT)
  • Hospital Del Mar (ES)
  • Universitat Pompeu Fabra (ES)
  • 7Computational Biophysics Laboratory (GRIB-IMIM), Pompeu Fabra University, PRBB, Barcelona, Spain.
  • 1Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
Corresponding author
  • Bardelli, Alberto
  • Montagut, Clara
Venue
Clinical Cancer Research
Published
2015-04-30
Volume
21
Issue
9
Pages
2157-2166
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2141630197
Cited by
271
References
31
Citations by year
2026: 18 · 2025: 12 · 2024: 26 · 2023: 15 · 2022: 35 · 2021: 19 · 2020: 23 · 2019: 28 · 2018: 24 · 2017: 35 · 2016: 27 · 2015: 8
FWCI
13.68
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
cetuximab resistance, colorectal cancer, EGFR mutation, anti-EGFR monoclonal antibody, KRAS, NRAS, BRAF, PIK3CA, panitumumab, drug resistance mechanisms
MeSH terms
Cetuximab, Antineoplastic Agents, DNA Mutational Analysis, Extracellular Space, Flow Cytometry, Humans, Mutation, Blotting, Western, Colorectal Neoplasms, Genes, erbB-1, Drug Resistance, Neoplasm, Cell Line, Tumor, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2821
The paper
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., Iglesias, M., Gavilan, E., Corti, G., Hobor, S., Crisafulli, G., Salido, M., Sánchez, J., Dalmases, A., Bellmunt, J., . . . Montagut, C. (2015). Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2821

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.